2022 International Conference on Gram Positive Pathogens

2022年革兰氏阳性病原体国际会议

• 批准号: 10539629
• 负责人: Francis Alonzo
• 金额: $ 0.7万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10539629
• 关键词: Adult; Anabolism; Antibiotic Resistance; Antibiotic-Associated Colitis; Antibiotics; Award; Bacteria; Bacterial Antibiotic Resistance; Biological Process; Biology; Burn injury; COVID-19 pandemic; Cell Communication; Cell Wall; Cells; Cellular biology; Clostridium difficile; Collaborations; Communities; Data; Enterocolitis; Epidemiology; Faculty; Fees; Florida; Fostering; Funding; Gram-Negative Bacteria; Gram-Positive Bacteria; Grant; Great Plains; Health care facility; Hospitals; Individual; Infection; Institution; International; Knowledge; Medical; Medical center; Membrane; Nebraska; Necrotizing fasciitis; Oral; Organism; Participant; Pathogenesis; Principal Investigator; Prokaryotic Cells; Protein Secretion; Proteins; Protocols documentation; Research; Research Personnel; Schools; Science; Scientist; Senior Scientist; Skin Tissue; Soft Tissue Infections; Travel; United States; United States Food and Drug Administration; Universities; career; graduate student; interest; meetings; methicillin resistant Staphylococcus aureus; mortality; novel therapeutics; pathogen; posters; professor; stem; supportive environment; symposium; undergraduate student

Project Summary The International Conference on Gram-Positive Pathogens (ICGPP) brings together scientists at all stages of their careers to exchange ideas and research strategies stemming from shared interests in gram-positive pathogens. This conference, initially held in 2006 and then continued in 2008, 2010, 2012, 2014, 2016, and 2018 because of participant enthusiasm, grew out of collaborations between investigators at the University of Nebraska Medical Center and other academic institutions in the great plains region of the United States. The overarching benefit of ICGPP is the opportunity for investigators to share the science, approaches, and protocols that are unique to gram-positive bacteria in contrast to gram-negative bacteria. While gram-positive pathogens cause myriad infections, ranging from antibiotic-associated colitis to necrotizing fasciitis, fundamental aspects of biological function such as protein secretion across single membranes, cell wall biosynthesis and protein anchoring, and cell-cell communication are shared between this group of medically important bacteria. The impact of gram-positive infections continues to grow, and antibiotic resistance remains a significant threat. As an example, Clostridioides difficile enterocolitis, once primarily associated with antibiotic use in hospitals, is now found in young, healthy adults that do not have an epidemiological relationship to a healthcare facility. Recent data suggests that infections caused by C. difficile are the leading cause of mortality among antibiotic-resistant bacteria in the US. In addition, community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strain USA300 continues to cause skin and soft tissue infections in schools, locker rooms, and hospitals in otherwise healthy individuals. This R13 application is requesting funds to support the 8th ICGPP to be held October 9 -12, 2022 in Omaha, Nebraska. Our diverse organizing and scientific committee comprises ten principal investigators from various academic institutions representing the full range of medically relevant gram- positive bacteria. Although other meetings exist in the US that cover various aspects of bacterial pathogenesis or prokaryotic biology, this is the only meeting focused specifically on gram-positive pathogenesis and biology, and which provides a collegial and supportive environment that fosters interactions between established investigators and junior scientists. Young scientists have the option of presenting their research in either poster or oral format and, in 2018, out of the 27 non-keynote speakers, 17 trainees and 8 Assistant Professors gave oral research presentations. Four internationally known scientists have already agreed to give keynote presentations at the 2022 ICGPP: Drs. Andreas Peschel (University of Tubingen), Drusilla Burns (U.S. Food and Drug Administration), Shonna McBride (Emory University) and Jose Lemos (University of Florida). To keep registration fees low for participants and to encourage the engagement of young investigators, we request funds to support travel of our keynote speakers and for 20 travel grants that will be awarded to trainees.

项目摘要 国际革兰氏阳性病原体会议（ICGPP）在各个阶段汇集了科学家 他们的职业是交换源于革兰氏阳性的共同利益而产生的思想和研究策略 病原体。这次会议最初于2006年举行，然后在2008年，2010年，2012年，2014年，2016年和2018年持续 由于参与者的热情，来自大学研究人员之间的合作 内布拉斯加州医疗中心和美国大平原地区的其他学术机构。这 ICGPP的总体好处是调查人员共享科学，方法和协议的机会 与革兰氏阴性细菌相比，革兰氏阳性细菌是独有的。而革兰氏阳性病原体 引起无数感染，从抗生素相关结肠炎到坏死性筋膜炎， 生物学功能，例如单个膜之间的蛋白质分泌，细胞壁生物合成和蛋白质 这组医学上重要的细菌之间共享锚定和细胞 - 细胞通信。这 革兰氏阳性感染的影响不断增长，抗生素耐药性仍然是一个重大威胁。作为 一个例子，曾经在医院中主要与抗生素使用有关的梭状芽胞杆菌艰难梭菌小肠结肠炎现在已 在与医疗机构没有流行病学关系的年轻，健康的成年人中发现。最近的 数据表明，艰难梭菌引起的感染是抗生素耐亡的主要原因 在美国的细菌。此外，社区获得的耐甲氧西林金黄色葡萄球菌（CA-MRSA） USA300劳累继续引起学校，更衣室和医院的皮肤和软组织感染 否则健康的个体。该R13申请要求资金支持要持有的第8个ICGPP 10月9日-12，2022年在内布拉斯加州的奥马哈。我们多样化的组织和科学委员会包括十个 来自各个学术机构的主要研究人员，代表了一系列与医学相关的革命 阳性细菌。尽管在美国存在其他会议，涵盖了细菌发病机理的各个方面 或原核生物学，这是唯一专门针对革兰氏阳性发病机理和生物学的会议， 并提供了一个联合和支持的环境，可以促进既定的互动 研究人员和初级科学家。年轻科学家可以选择在任一海报中介绍他们的研究 或口服格式，2018年，在27位非钥匙扬声器中，有17名学员和8位助理教授给予 口头研究演讲。四名国际知名科学家已经同意提供主题演讲 2022 ICGPP的演示文稿：Drs。 Andreas Peschel（Tubingen大学），Drusilla Burns（美国食品和 药物管理局），肖纳·麦克布赖德（埃默里大学）和何塞·莱莫斯（佛罗里达大学）。保持 参与者的注册费低，并鼓励年轻调查人员的参与，我们要求资金 为了支持我们的主旨演讲者的旅行，并为20个旅行补助金提供给受训者。